Information Provided By: 
Fly News Breaks for December 5, 2019
AUPH
Dec 5, 2019 | 08:28 EDT
RBC Capital analyst Douglas Miehm raised his price target on Aurinia Pharmaceuticals to $20 and kept his Outperform rating after a "robust" read-out for its Phase 3 voclosporin trial data in lupus nephritis, which demonstrated a superior profile over the standard of care. The analyst notes that the the risk profile for the company has "improved significantly" with the release, expecting Aurinia to gain approval for voclosporin in late 2020/early 2021 with a launch coming some time in 2021.
News For AUPH From the Last 2 Days
There are no results for your query AUPH
